

Adnavance Technologies to Present at BIO National Venture Conference

April 21, 2008 - - VANCOUVER, British Columbia & SAN DIEGO - - Adnavance Technologies Inc., a developer of new direct detection molecular diagnostic tests for medical applications, announced today that Randy White, Chief Executive Officer, will present at the BIO National Venture Conference on Tuesday, April 22, 2008, at 4:00 p.m. Eastern time. The conference is being held April 22-23 at the Hyatt Regency Cambridge Hotel in Cambridge, Massachusetts.

About Adnavance Technologies Inc.

Adnavance is a molecular diagnostic company focused on development of DNA-based tests using the Company's patented metalized-DNA (M-DNA™) platform. M-DNA™ is based on the conducting properties of hybridized DNA. Under strict reaction conditions, certain metal ions can enter the central core of hybridized DNA and displace the hydrogen bonds forming the equivalent of a metal wire in the center of the DNA and making the DNA highly conductive. The Company uses a microarray of 10-micron electrodes to detect the M-DNA™ and the inherent ultra-sensitivity arises from the differential change in conductivity between hybridized DNA and metalized DNA. This change in conductivity is so large that it may obviate the need for target amplification used in current molecular-based tests. Adnavance scientists were the first to discover the M-DNA™ phenomenon, and the Company believes its technology platform will open new molecular testing markets world-wide.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate," and similar words indicating uncertainty in facts and figures. Although Adnavance believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove correct. Actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with the technology development process, the risk that Adnavance technology will not gain market acceptance, the risks associated with dependence upon key personnel and the need for additional financing to commercialize the technology platform.